Social phobia: the clinical efficacy and tolerability of the monoamine oxidase ‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study

Publisher Website
Google Scholar
Abstract
Seventy‐seven patients with a primary diagnosis of social phobia (DSM‐III‐R) were randomized to treatment with the reversible and selective monoamine oxidase type A inhibitor brofaromine (n= 37) or placebo (n= 40) for 12 weeks in a double‐blind trial. A fixed dose of 150 mg/day or a matching placebo was given after a 2‐week dose titration phase. Patients with additional diagnoses of simple phobia, generalized anxiety disorder, dysthymia or major depressive disorder currently in remission were accepted. Patients with other Axis I mental disorders were excluded. In the brofaromine group, 78% of the patients scored much or very much improved on the Clinical Global Impression scale compared with 23% in the placebo group. The anxiety and avoidance scores on the Liebowitz Social Anxiety Scale (LSAS) were significantly reduced in favor of brofaromine. The clinical effects were not significantly correlated with the plasma concentration of brofaromine. After 12 weeks the brofaromine group scored significantly Jower than the placebo group on a core depression part of the Montgomery‐Åsberg Depressid Rating Scale. After 12 weeks of treatment the brofaromine group had significantly higher total scores on the LSAS than an age‐ and gender‐matched group of healthy controls. The brofaromine group improved further during 9‐month follow‐up treatment period, whereas 60% of the placebo responders who continued long‐term treatment relapsed. The most common side effects in the brofaromine group were sleep disturbances, dry mouth and nausea.